TrialScientific reports2019

Sex-Related Differences in Impact on Safety of Pharmacogenetic Profile for Colon Cancer Patients Treated with FOLFOX-4 or XELOX Adjuvant Chemotherapy.

Annamaria Ruzzo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.